GLP-1 Isn't a Smaller-Portions Story. It's the Biggest Menu Engineering Opportunity in 15 Years.
1 in 8 U.S. adults are on GLP-1 drugs. Headlines call it a revenue problem. The data says it's a category opportunity. Here's the menu engineering playbook independents are using to capture it.

Approximately one in eight U.S. adults is currently taking a GLP-1 drug for diabetes or weight management (KFF Health Tracking Poll, November 2025). J.P. Morgan projects the user base will roughly double or triple by 2030. The U.S. obesity rate fell for the first time in a decade in 2025. Generic semaglutide became available in India, Brazil, Canada, and over 100 other countries on March 20, 2026, with patents in the U.S. extended into 2032 due to a thicket of follow-on patents.
The trade press has been covering this as a problem. Bloomberg, WSJ, and Reuters have all run versions of the same story: GLP-1 users eat 21% fewer calories on average (Circana), spend about a third less on food overall, and order smaller meals. J.P. Morgan estimates a $55 billion reduction in U.S. food and beverage revenue annually by 2030 to 2034 from the cumulative effect.
Read it that way and the strategic answer is defensive. Smaller portion sections. Lighter menus. Damage control on the check average. That's the lens Olive Garden, P.F. Chang's, Cheesecake Factory, and McDonald's are operating from.
Read the same data more carefully and a different story shows up. GLP-1 users aren't ordering less of everything. They're radically reshuffling category preferences. Less of: appetizers, sweets, sugary drinks, alcohol, large entrees, desserts. More of: protein-dense items, fiber-rich items, smaller-portion entrees, water and zero-calorie drinks. About the same of: dining-out frequency. Most of these customers are still walking through the door. They're just buying a different basket.
That's not a revenue collapse. That's a menu category shift, and a fast one. The restaurants that recognize the shift early are going to recategorize, reprice, and reposition faster than the chains can. The trade press headline is "smaller portions." The actual opportunity is reshaped categories at the same total ticket value, or higher, on a customer base that's still expanding.
This is what menu engineering looks like when the macroenvironment forces a real category shift. The last time the industry saw something this big was the rise of fast casual in the mid-2000s.
What's actually happening to the basket
The behavior data is more specific than the headline coverage suggests, and worth understanding category by category.
Protein is up. McDonald's CEO Chris Kempczinski told investors on the February 2026 earnings call that GLP-1 customers "tend to favor protein-rich meals." Cuba Libre and other early movers built high-protein, smaller-portion sections with input from physicians. McDonald's is testing high-protein options including reworked Snack Wraps, Sausage Biscuit sandwiches, and McCrispy Strips for this exact segment.
Fiber is up. General Mills, Danone, and Nestlé are marketing high-fiber products explicitly around satiety and metabolic health. The same shift is showing up at the restaurant level, with greens-forward bowls, whole-grain bases, and bean and legume sides moving up the mix.
Smaller portions are up, but specifically targeted. Clinton Hall, a New York City gastropub chain, generated significant press by introducing a "Teeny Weeny Mini Meal" with a mini burger, mini fries, and mini beer alongside its regular menu. Olive Garden introduced a "lighter portions" section. P.F. Chang's added smaller-portion options for its entrees. The format isn't a kids menu or a senior menu. It's a deliberate adult-targeted format priced at roughly 65 to 75 percent of the full-size version, with margin discipline maintained.
Alcohol is down significantly. GLP-1 users frequently reduce or eliminate alcohol consumption, partly due to physical sensitivity to the drug and partly due to reduced cravings. Restaurants previously generating 25 to 35 percent of revenue from bar are seeing measurable shifts. The replacement: zero-proof cocktails, sparkling water programs, premium non-alcoholic beer, kombucha.
Sweets and desserts are down. Sugar cravings drop significantly on GLP-1. Dessert attach rates have measurably decreased. The opportunity here is shifting the post-meal moment from dessert to coffee, tea, or a small savory option.
Appetizers are down. GLP-1 users feel full faster, so the appetizer-to-entree cycle that previously contributed meaningfully to ticket size is being compressed. Tables that previously ordered two apps, two entrees, and a shared dessert now order one app and two entrees, or two entrees alone.
The cumulative effect on the average GLP-1 user's check is a 25 to 35 percent reduction if the menu doesn't adapt. The same customer on a menu that's positioned for their basket can produce a ticket within 5 to 10 percent of their pre-GLP-1 spending, on a higher-margin mix.
Why the chains can't capture this fast enough
Olive Garden, Cheesecake Factory, P.F. Chang's, McDonald's, and Cuba Libre have all moved on this, which is encouraging. The pace they can move at is the constraint.
A chain takes 12 to 24 months to add a new menu category. The Olive Garden "lighter portions" section was a quarters-long initiative requiring corporate approval, supply chain alignment, recipe development at the test kitchen, franchisee approval, training rollout across hundreds of locations, marketing campaign coordination, third-party delivery listing updates, and POS system integration. The chain version of "add a high-protein section" is a year of work.
A single-location independent can add a high-protein quick-meal section by Tuesday's lunch service. Reorder existing menu items into a new section header. Add three or four new SKUs that lean into the category. Tag items visibly with protein and fiber content. Update the digital menu. Brief the staff at shift huddle. Done.
The same speed-of-change advantage that's driving the closure wave (Bar Louie, On the Border, Outback) is the advantage that captures the GLP-1 segment. The chains will get there eventually. By then, the local independents in their trade areas will have spent 24 months training the segment to find them first.
This is why GLP-1 isn't just a category opportunity. It's specifically a category opportunity that favors operators with menu agility. A static printed menu makes the play expensive. A digital menu makes it nearly free.
The menu engineering playbook
1. Build a high-protein, high-fiber section
The fastest entry point. Most independents already have items that qualify (grilled chicken bowls, salmon plates, bean-and-grain bowls). Pull them out of their existing categories, group them visibly into a section with a name that signals the positioning without being clinical. "Power Bowls," "Protein Plates," "Fuel Menu," whatever fits the brand. Tag each item with grams of protein and fiber. The signal does the work.
2. Offer mini and full versions of high-volume items
The mini-meal format works because it lets a GLP-1 user dine without leaving food behind and without paying for food they can't eat. Pick three or four of your highest-traffic items. Offer a mini version at 65 to 75 percent of the price and 50 to 60 percent of the portion. Price for margin discipline. The mini should produce 80 to 90 percent of the gross margin of the full size despite a smaller absolute price. A digital menu can show both versions side by side without making the full menu feel cluttered. A printed menu can't.
3. Build a credible zero-proof drink section
Don't tuck two mocktails at the end of the cocktail list. Build a dedicated zero-proof section with the same care as the cocktail program. Premium non-alcoholic spirits (Seedlip, Lyre's, Athletic Brewing), serious sparkling water programs, kombucha by the glass, cold-pressed juices. GLP-1 users will reliably trade up here. Many non-GLP-1 users will too. The category has independent legs.
4. Use daypart switching to surface the right menu
A GLP-1 user at lunch is a different customer than a non-GLP-1 user at dinner. The menu that converts at noon should lead with high-protein, smaller-portion, lower-calorie options. The menu that converts at 7 PM can lead with the regular menu while keeping the high-protein and mini options visible. This is impossible without a digital menu. Trivial with one.
5. Track category mix as a leading indicator
The metric that matters isn't whether you've added a high-protein section. It's what percentage of your tickets include an item from that section, how that percentage is trending month over month, and how the ticket value of those tickets compares to your overall average. Operators who track this weekly will catch the GLP-1 customer migration in their data three to six months before operators who don't.
6. Don't try to identify individual GLP-1 customers
The temptation is to design "Ozempic-friendly menus" and market them specifically. The better strategy is to design menus that work for people whose appetite has changed for any reason (GLP-1, intermittent fasting, post-bariatric surgery, dietary preference) and let the signal pull the right customer in. Marketing the GLP-1 angle directly is brittle (the drugs will get rebranded, replaced, or destigmatized in unpredictable ways). Designing for the behavior is durable.
7. Tag macros visibly
The single highest-leverage menu design move for the GLP-1 segment is making protein, fiber, and calorie information legible without making the menu feel medical. A small set of icons next to each item (a "P" for protein-forward, an "F" for fiber-forward, a "L" for lighter) does the work. GLP-1 users are doing this math in their heads anyway. Putting the information on the menu reduces their decision time and increases conversion.
The bigger pattern
There's a recurring shape to category shifts in casual dining. A new behavioral driver shows up (GMOs, gluten sensitivity, plant-based, keto, intermittent fasting). The trade press covers it as a problem. The chains respond slowly with one new section. The fast casual segment lifts a generation of new concepts built around the shift (Sweetgreen on fresh, Cava on Mediterranean, Chipotle on customizable proteins). The independents who positioned early capture share.
GLP-1 is bigger than any prior category shift because the underlying driver isn't a preference or a fad. It's a medication with measurable physical effects on appetite. The user base is growing globally, churning, and growing again. Even with high discontinuation rates (about half of today's active users will have stopped by next year), the net population is on a clear growth trajectory. Patent expirations in India, Brazil, Canada, and 100+ other countries through 2026 will accelerate user growth at the same time U.S. consumer access expands via telehealth and compounded pharmacy alternatives.
This isn't a 12-month story. It's a 5-year structural shift to a customer base that orders differently, drinks differently, snacks differently, and dines differently. The casual dining brands that come out of the next five years stronger will be the ones who saw the category shift early, reshaped their menu architecture to serve both ends of the appetite spectrum, and moved fast enough to train the segment to find them.
Restaurants competing on portion size are competing on the wrong axis. Restaurants competing on menu architecture are competing on the right one. Menu architecture is a software problem, not a printing problem.
See how Menuthere makes GLP-1 menu engineering a Tuesday afternoon decision. Live digital menus with visible macro tagging, mini and full portion display, daypart-aware section surfacing, and analytics on category mix. The agility you need to capture the next 5 years of casual dining.
Sources: KFF Health Tracking Poll (November 2025), Circana GLP-1 consumer behavior data, J.P. Morgan Global Research GLP-1 market projections (February 2026), CNBC GLP-1 restaurant coverage (March 2026), Tasting Table / AOL GLP-1 menu reshaping (2026), Institute of Culinary Education GLP-1 strategy guide, Superior Seating GLP-1 industry analysis (May 2026), McGill Journal of Economics "Ozempic Effect" research (March 2026), Cornell research via FoodBev, EY-Parthenon GLP-1 consumer survey, MLex semaglutide patent coverage (April 2026), C&EN ACS GLP-1 patent analysis.
